NCT04098653

Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT

Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Myeloid Tumors Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 196 (estimated)
• Sponsor: Nanfang Hospital, Southern Medical University · Academic / Other
• Sex: All
• Age: 14 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Recent studies have demonstrated that allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be a valuable treatment choice for myeloid tumors, such as acute myeloid leukemia and myelodysplastic syndrome. Unfortunately, some patients relapsed after allo-HSCT. In this prospective randomized controlled study, the safety and efficacy of Decitabine + BUCY and BUCY myeloablative conditioning regimens in myeloid tumors undergoing allo-HSCT are evaluated.

Detailed description

Recent studies have demonstrated that allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be a valuable treatment choice for myeloid tumors, such as acute myeloid leukemia and myelodysplastic syndrome. BUCY conditioning regimen is the standard myeloablative regimen for myeloid tumors undergoing allo-HSCT. However, it appears to have higher relapse rate and lower survival. To reduce the relapse rate and improve the survival, decitabine is added in the conditioning regimen. In this prospective randomized controlled study, the safety and efficacy of Decitabine + BUCY and BUCY myeloablative conditioning regimens in myeloid tumors undergoing allo-HSCT are evaluated.

Conditions

• Allogeneic Hematopoietic Stem Cell Transplantation
• Conditioning
• Myeloid Tumors

Interventions

Type	Name	Description
DRUG	Decitabine	Decitabine was administered at 20mg/m2/day on days -14 and -10.
DRUG	Busulfan (BU)	Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
DRUG	Cyclophosphamide (CY)	Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.

Timeline

• Start date: 2019-09-01
• Primary completion: 2022-08-01
• Completion: 2023-08-01
• First posted: 2019-09-23
• Last updated: 2019-09-23

Locations

1 site across 1 country: China